65,437 trials
Intermittent Explosive Disorder · Childhood Aggression · Oppositional Defiant Disorder
Primary: Number of Participants That Were Responders — 0; 5 Participants
Mild Cognitive Impairment · Dementia
Primary: eSAGE Score Compared to the Sum of the Neuropsychological Measures. — 0.7292 spearman rank correlation
Breast Cancer
Primary: Progression-Free Survival — 12.9; 12.9 months — p=0.8934
Sarcoma · Liposarcoma
Primary: Progression Free Survival at 12 Weeks — 66; 57.2 percentage of particpants
Contact Lens Solutions
Primary: Overall Comfort Score (Senofilcon A Lens) — 64.42; 59.73; 63.75; 63.47 units on a scale
Neoplasms
Primary: Feasibility and Acceptability of Using a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by AYA With Cancer. — 21; 13 Participants
Substance Abuse
Primary: Number of Participants With MI Skillfulness — 48; 43 Participants
Hepatitis C
Primary: Percentage of Participants Who Experienced Relapse12overall With and Without New HCV Infection — 0.2; 0.2 percentage of participants
Tourette Syndrome
Primary: Change From Baseline in Total Tic Score at Day 70 — -5.0; -14.29 units on a scale — p=0.0259
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants With Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers >=1:128 — 43; 56; 56; 15 Participants
Catheter-Associated Infections · Catheter-Related Infections
Primary: Number of Participants With Drug-Related Hypotension — 0 Participants
Prostate Cancer
Primary: Prostate Biopsy — 0; 3; 8; 11 participants
Obesity
Primary: Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group — 25; 20 Participants
Tourette Syndrome
Primary: Change in TTS — -14.29 units on a scale
Malnutrition
Primary: The Percent of Participants Identified With Malnutrition Using the NRS 2002 and ThedaCare Nutrition Risk Screen — 63.5; 98.8; 94.3; 74 percentage of participants